TEAM MEMBERS

DR. SARAH AITKEN

Assistant Professor - Yale University

Clinician Scientist - University of Cambridge

Sarah Aitken, MBChB PhD, is an Assistant Professor of Pathology and a member of the Center of Molecular and Cellular Oncology (CMCO) at Yale Cancer Center. She holds a CRUK Clinician Scientist Fellowship (University of Cambridge) and is a Board Certified Pathologist, specialised in gastrointestinal and molecular pathology.

Sarah trained in Medicine at the University of Edinburgh, with an intercalated BMedSci in Experimental Pathology and postgraduate MSc in Translational Medicine. She undertook a mixed experimental-computational PhD at the CRUK Cambridge Institute, followed by an EMBO bioinformatics fellowship at the IRB Barcelona. She then completed her Histopathology training (Board Certification) in Cambridge as an NIHR Academic Clinical Fellow and subsequently NIHR Clinical Lecturer. Sarah started her independent research group at the University of Cambridge, before relocating to Yale University in 2024.

Follow: Bsky @s-j-aitken, X @S_J_Aitken

YOU...?

We are hiring!

Postdoctoral associates

- Computational cancer biology (Yale University)

- Cancer biology and genomics (Yale University)

Lab manager

Candidates should email Dr Aitken with the following:

1. Cover letter: brief statement of research experience and interests, how you match the criteria, and your motivation to join the team.

2. CV

3. Contact information (including email address and phone number) for three referees, one of whom should be your most recent line manager.

Please include “Postdoctoral Associate (Computational/Experimental), Your full name” in the subject line.

We will review applications on a rolling basis.

DR. CLAUDIA ARNEDO PAC

Postdoc - University of Cambridge

MRC

Claudia Arnedo Pac is a postdoctoral researcher in computational biology.

Claudia undertook her PhD in Biomedicine and Bioinformatics with Prof. Núria López-Bigas at the Institute for Research in Biomedicine (IRB) Barcelona, Spain.

Prior to that, Claudia completed her undergraduate studies in Biomedicine (University of Barcelona) and Masters in Bioinformatics for Health Sciences (Pompeu Fabra University, Barcelona, Spain).

Follow: @clarnedo

DR. BÁRBARA HERNANDO

Visiting Research Scientist - Yale University

La Caixa Junior Leader, CNIO, Madrid, Spain

Barbara Hernando is a la Caixa Junior Leader at the Spanish National Cancer Research Center (CNIO), Madrid, Spain.

She is currently on sabbatical with us at Yale!

Follow: @bhernando.bsky.social

DR. KLASKE SCHUKKEN

Postdoc - Yale University

Klaske Schukken is a Postdoctoral Associate at Yale University researching aneuploidy in cancers.

Klaske undertook her PhD in the lab of Prof. Floris Foijer at the University of Groningen, in the Netherlands. There she researched chromosome instability in cancer. Prior to that Klaske completed her undergraduate degree in Biology at Cornell University, USA.

Klaske’s project involves generating a panel of aneuploid subclones of near euploid cell lines and using CRISPR screening techniques to identify aneuploid-specific dependencies. She also uses bioinformatic analysis to investigate protein expression and patient survival in aneuploid cancers.

HASHIM AHMED NUR

PhD student - University of Cambridge

MRC

Hashim Ahmed Nur is a PhD student at the MRC Toxicology Unit, University of Cambridge. In his PhD, he is exploring the molecular and genomic responses to DNA damaging agents.

Prior to commencing his PhD, he completed a Masters by research in cancer biology at Imperial College London where he carried out two distinct research projects.

Hashim’s research interests include drug development and how targeted therapies can be used to overcome chemotherapy resistance in the treatment of cancer.

EMMA REILLY

PhD student - University of Cambridge

AstraZeneca

Emma Reilly is a PhD student based in Steve Jackson's lab at CRUK - Cambridge Institute, and AstraZeneca.

JACOB MILLER

MD-PhD student - Yale University

Jacob is an MD-PhD student interested in elucidating targetable mechanisms of genomic instability and epigenetic dysregulation that contribute to tumourigenesis, cancer progression, and therapeutic resistance.